Etiology and Epidemiology of Chronic Myeloid Leukemia
Time of observation Number of patients Incidence crude Incidence (WSP)a SEER [28] 1998–2000 – – 1.8b 2003–2007 4,653 – 1.7b France [35] 1985–2006 906 – 0.8 Swedish Cancer…
ONCOLOGY
Treatment of Chronic Lymphocytic Leukemia and Related Disorders
Working groups: NCIWG/IWCLL [2] Parameter Diagnosis Lymphocytes (× 109/L) >5; ≥1 B-cell marker (CD19, CD20, CD23) + CD5 Atypical cells (%) (e.g. prolymphocytes) <55 Duration of lymphocytosis At least…
of Hepatocellular Carcinoma: Current Concepts
Ultrasound CT MRI Advantages Low cost Low cost No radiation Availability Availability High contrast resolution Useful for screening and surveillance Quick Liver-specific agents High spatial resolution Functional MRI Highest…
Carcinoma Biology
Fig. 1 IL-6/STAT3 signaling pathway. Shown is a schematic figure of the IL-6/JAK/STAT signaling pathway. Binding of IL-6 to its cognate receptor results in phosphorylation of JAK1/2 with subsequent autophosphorylation of…
for Hepatocellular Carcinoma: The North American Experience
Tumor classification Definition Stage Criteria T0, N0, M0 Not found Stage I T1 T1 One nodule <2.0 cm Stage II T2 T2 One nodule 2.0–5.0 cm; 2 or 3 nodules, all <3.0 cm Stage III T3 T3…
Resection for Hepatocellular Carcinoma in the Noncirrhotic: The Western Experience
Without underlying liver disease With underlying liver disease p value Number 82 124 − Liver disease, n (%) HBV (HBsAg+) HCV (anti-HCV Ab+) NASH Alcoholic liver disease Other −…
Resection of Hepatocellular Carcinoma
Fig. 1 Algorithm for management of transplantable hepatocellular carcinoma at Henri Mondor Hospital, Creteil, France [3] For patients with a solitary HCC<5 cm, no evidence of extrahepatic tumor burden, compensated liver disease,…
Management of Hepatocellular Carcinoma
Classification Stages/Scores Parameters Survival/Stage (%) Hepatitis (%) Study area of origin Tumor characteristics Liver function Health status Hepatitis B Hepatitis C Both Okuda I, II, III </>50 % liver involvement Bilirubin,…
90 Microspheres for the Treatment of Hepatocellular Carcinoma
Characteristic TheraSphere® SIR-Sphere® Isotope 90Y 90Y Half-Life (h) 64.2 64.2 Particle Size (μm) 20–30 20–60 Range of spheres per vial 1.2–8.0 million 40–80 million Activity per sphere (Bq) 2500 50…
Cancer and Liver Transplantation: A Western Experience
Stage AJCC- clinical staging AJCC-staging I 81 (51 %) 60 (38 %) II 57 (36 %) 49 (31 %) III 7 (4 %) 9 (6 %) IV 0 1 (0.6 %) No lesions 14 (9 %) 12 (7 %)…
